Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a medical device company focused on device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine. This news page aggregates company-issued updates and market-moving announcements related to ClearPoint Neuro’s neurosurgical navigation systems, laser therapy platforms, intracranial fluid management technologies, and central nervous system drug delivery services.
Readers can follow earnings and financial updates, such as preliminary unaudited revenue results and quarterly reports furnished via Form 8-K, which outline trends in biologics and drug delivery revenue, neurosurgery navigation and therapy revenue, and capital equipment and software sales. News items also cover strategic transactions, including the completed acquisition of IRRAS Holdings, Inc., which adds the IRRAflow active fluid-exchange system and expands ClearPoint Neuro’s presence in neurocritical care and intracranial bleeding management.
ClearPoint Neuro’s news flow frequently highlights regulatory milestones like FDA 510(k) clearances, including expanded MRI compatibility for the ClearPoint Prism Neuro Laser Therapy System, and international regulatory approvals that extend product use to additional countries. The company also reports on clinical and scientific developments, such as Phase I–II study results in glioblastoma and grade 4 astrocytoma using ClearPoint Prism, as well as the development and demonstration of its proprietary Robotic Neuro-Navigation System.
Investors and observers can also track partnership and conference activity, including updates on more than 60 active biopharma partners, participation in global healthcare conferences, and progress at ClearPoint Advanced Laboratories. Bookmark this page to review historical and ongoing CLPT news related to neurosurgical devices, therapy delivery platforms, and the company’s role in enabling cell and gene therapy programs.
ClearPoint Neuro (Nasdaq: CLPT) announced a $7.5 million strategic investment from Petrichor Healthcare Capital Management, amending their January 2020 financing agreement. The new terms include a conversion price increase from $6.00 to $10.14 per share and a reduced interest rate of 7%, down from 9%. The funds will support global product commercialization, strategic partnerships, and R&D. The company expects to enter 2021 with cash balances exceeding $20 million, positioning itself for growth in next-generation therapies.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced a significant milestone with the completion of its 4,000th neurosurgical procedure using the ClearPoint Neuro Navigation System at Dartmouth-Hitchcock Medical Center. This advanced MRI-guided technology is now utilized at 60 leading neurosurgical centers in the US for procedures like deep brain stimulation and biopsies. ClearPoint's mission focuses on improving patient outcomes for complex neurological disorders, supported by a team of clinical specialists and partnerships with biologics and drug delivery companies.
ClearPoint Neuro reported a record revenue of $3.5 million for Q3 2020, reflecting a 20% increase year-over-year. The increase was fueled by a 162% rise in biologics and drug delivery revenue, totaling $1.5 million, thanks to new clinical service relationships. However, functional neurosurgery navigation revenue fell 1% to $1.8 million, and capital equipment revenue dropped 48% to $0.2 million. Operating expenses surged by 43% to $4.1 million, leading to an operating loss of $1.3 million. Cash reserves stood at $14.7 million as of September 30, 2020.
ClearPoint Neuro (Nasdaq: CLPT) will release its 2020 third quarter financial results on November 10, 2020, after market close. A conference call to discuss the results will follow at 4:30 p.m. Eastern. Interested participants can join via phone or through a live webcast on the company's website. ClearPoint Neuro focuses on improving therapies for neurological disorders with its FDA-cleared ClearPoint® Neuro Navigation System, currently installed in 60 clinical sites. Risks include uncertainties related to COVID-19 and future revenue generation from its products.
ClearPoint Neuro (CLPT) has appointed Danilo D'Alessandro as its new Chief Financial Officer, succeeding Harold Hurwitz, who plans to retire in 2021. D'Alessandro, with extensive experience from Philips, will start as Vice President of Finance on September 29, 2020, and officially assume the CFO role on January 1, 2021. The transition is expected to drive growth and profitability for the company as it aims to expand its global portfolio. ClearPoint's mission is to enhance therapies for complex neurological disorders.
ClearPoint Neuro reported its second quarter financial results for 2020, revealing total revenues of approximately $2.5 million, a 5% decrease year-over-year. The functional neurosurgery revenue dropped 38% to $1.0 million due to COVID-19's impact on elective surgeries. However, biologics and drug delivery revenue surged 183% to $1.2 million, driven by new partnerships. Operating expenses increased 15% to $3.3 million, with an operating loss of $1.5 million. Cash reserves stood at $16.0 million as of June 30, 2020, amid ongoing uncertainty regarding the recovery of elective procedures.
ClearPoint Neuro (Nasdaq: CLPT) plans to release its financial results for Q2 2020 on August 12, 2020, post-market. A conference call will follow at 4:30 p.m. Eastern, where analysts and investors can participate by calling (877) 407-9034. The company's portfolio focuses on advanced neurological therapies, with the ClearPoint Neuro Navigation System actively utilized in 60 clinical sites across the U.S. The firm is navigating uncertainties, including the impacts of COVID-19, but remains committed to its mission of enhancing life quality for patients with neurological disorders.
ClearPoint Neuro reported a 26% year-over-year revenue increase for Q1 2020, reaching approximately $3.1 million, driven by a 169% rise in biologics and drug delivery revenues to $1.0 million. However, functional neurosurgery revenues saw only a 5% increase due to the COVID-19 pandemic, which curtailed elective surgeries. Operating expenses also surged by 33% to $3.4 million. The company withdrew its 2020 revenue forecasts after a significant drop in case volumes, experiencing an 85% reduction in April procedures. Cash reserves stood at $17.0 million as of March 31, 2020.